Anakinra in Dengue With Hyperinflammation ( AnaDen )
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation
as compared to placebo
Primary Objective:
To evaluate the efficacy of Anakinra in moderate-severe dengue patients with
hyperinflammation.
Secondary Objectives:
- To assess the safety of anakinra therapy in dengue with hyperinflammation
- To assess the effect of anakinra therapy in patients with dengue on physiological,
clinical and virological parameters
- To assess the immunomodulation effects of anakinra in dengue
- Immune cell signatures in dengue with and without anakinra
- To assess difference in gene expression between treatment group compared to
non-treatment population
Phase:
Phase 2
Details
Lead Sponsor:
Oxford University Clinical Research Unit, Vietnam
Collaborator:
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam